🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHas anyone dealt with blood pressure went from scary to perfect - anyone else?? Page 5

Has anyone dealt with blood pressure went from scary to perfect - anyone else??

sophie_paris Thu, Oct 31, 2024 at 3:24 AM 39 replies 2,318 viewsPage 5 of 8
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Nov 20, 2024 at 11:16 PM#21
Dr.PathRoch said:
Lp(a) and cardiovascular risk: a nuance that matters.

Senior perspective on cardiovascular risk: I'm 65 years old and started this journey skeptically. My endocrinologist recommended it after years of failed interventions.

11 months later: down 48 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

37 10Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 34 others
Reply Quote Save Share Report
NauseaFreeNow
Member
345
1,234
Aug 2024
Indiana
Nov 28, 2024 at 6:06 AM#22
Dr.PathRoch said:
Lp(a) and cardiovascular risk: a nuance that matters.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

References:
[1] Zheng SL, et al. Lancet Diabetes Endocrinol. 2023;11(12):869-879.
38 11maya_sedona, stefan_berlin, Dr.EM_Chicago and 35 others
Reply Quote Save Share Report
SandraNC_45
Member
312
1,345
Sep 2024
Charlotte, NC
Dec 5, 2024 at 1:00 PM#23
Dr.PathRoch said:
Lp(a) and cardiovascular risk: a nuance that matters.

Bookmarking. The distinction being drawn above is the one nobody else makes. Sending this to two other people who asked me the same thing last week.

Last edited: Dec 5, 2024 at 6:00 PM
39 12NicoleRaleigh, james_edin, FranDenver and 36 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
pete_nash
Member
312
1,345
Aug 2024
Nashville, TN
Dec 12, 2024 at 7:58 PM#24

From the other side of the consultation, briefly.

Dr.PathRoch said:
...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

  • Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
  • Published in NEJM, JAMA, Lancet (not press releases)
  • Replicated across multiple independent research groups
  • Proven cardiovascular and renal benefits beyond weight loss
  • Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.

40 13SarahChen_PharmD, sarah.morrison, NeuroNate and 37 others
Reply Quote Save Share Report
sarah_TO
Member
278
1,234
Sep 2024
Toronto, CA
Dec 20, 2024 at 3:00 AM#25
pete_nash said:
Dr.PathRoch said: ...cardiovascular risk is just another fad...

Mine went the same way, slower.

Last edited: Dec 20, 2024 at 7:00 AM
41 14DanielChem_CHI, marco_milano, pam_columbus and 38 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register